Granted Patent
B2
US 12,201,603 · App. 18/169,716 · Granted Jan 21, 2025
Bicyclic compound and use thereof for medical purposes
Inventors:
Tohru Kambe (Osaka, JP); Toru Maruyama (Osaka, JP); Shinsaku Yamane (Osaka, JP); Satoshi Nakayama (Osaka, JP); Kousuke Tani (Osaka, JP)
Assignee:
ONO PHARMACEUTICAL CO., LTD.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
Claims (2)
1. A pharmaceutical composition comprising the compound of formula (I):
wherein the composition is an eye drop formulation.
Priority Claims (1)
JP 2009-175246
· Jul 28, 2009
· national
Continuity (9)
Continuation
13384383
References Cited (54)
US 4230721A
· Gandolfi et al.
· 1980
[cited by applicant]
US 4367237A
· Wakatsuka et al.
· 1983
[cited by applicant]
US 4490537A
· Johnson
· 1984
[cited by applicant]
US 6583174B1
· Ueno et al.
· 2003
[cited by applicant]
US 8614340B2
· Kambe
· 2013
[cited by examiner]
US 8962868B2
· Kambe
· 2015
[cited by examiner]
US 9029574B2
· Kambe
· 2015
[cited by examiner]
US 9388157B2
· Kambe
· 2016
[cited by examiner]
US 9889114B2
· Kambe
· 2018
[cited by examiner]
JP 5037780A
· 1975
[cited by applicant]
JP 5384959A
· 1978
[cited by applicant]
JP 53132573A
· 1978
[cited by applicant]
JP 5573678A
· 1980
[cited by applicant]
JP 64068367A
· 1989
[cited by applicant]
JP 2013532174A
· 2013
[cited by applicant]
WO 0127099A2
· 2001
[cited by applicant]
WO 2007149829A2
· 2007
[cited by applicant]
WO 2011013651A1
· 2011
[cited by applicant]
WO 2012102355A1
· 2012
[cited by applicant]
WO 2012102357A1
· 2012
[cited by applicant]
Feldman, Understanding ‘Evergreening’ : Making Minor Modifications Of Existing Medications To Extend Protections, Health Affairs Jun. 2022 41:6, 801-804.
[cited by examiner]
Dwivedi, Evergreening: A deceptive device in patent rights, Technology in Society 32 (2010) 324-330.
[cited by examiner]
Extended European Search Report issued on Dec. 3, 2012 in European patent application No. 10 804 397.7.
[cited by applicant]
International Search Report (PCT/ISA/210), issued by the International Searching Authority in International Application No. PCT/JP2010/062587 on Sep. 14, 2010.
[cited by applicant]
International Search Report, dated Mar. 13, 2012, issued in International Patent Application No. PCT/JP2012/051721.
[cited by applicant]
International Search Report, dated Mar. 13, 2012, issued in International Patent Application No. PCT/JP2012/051718.
[cited by applicant]
West, Solid State Chemistry and Its Applications, John Wiley & Sons, 1984.
[cited by applicant]
Wolff, Burger's medicinal Chemistry and Drug Discovery, vol. 1, Principles and Practice, John Wiley & Sons, New York, 1997.
[cited by applicant]
Yamane, et al. Investigative Ophthalmology & Visual Science (2015), 56(4), 2547-2552.
[cited by applicant]
International Search Report (PCT/ISA/210) dated Oct. 3, 2017, issued by the International Searching Authority in International Application No. PCT/JP2017/024031.
[cited by applicant]
A. L. Hurski et al., “Synthesis of Epothilone with the Forced Application of Oxycyclopropane Intermediates”, Russian Journal of Organic Chemistry, vol. 47, No. 11, Pleiades Publishing, Jul. 18, 2011, pp. 1653-1674.
[cited by applicant]
Isamu Sugimoto et al., “Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists”, ACS Medicinal Chemistry Letters, vol. 8, No. 1, American Chemical Society…
[cited by applicant]
Marriott, Pharmaceutical Compound and Dispensing, Second Edition, 2010, 1-288.
[cited by applicant]
Ansel, Pharmaceutical Dosage Forms and Drug Delivery Systems, 1999.
[cited by applicant]
Luciano Quaranta et al. “Prostaglandin Analogues (PGAs) And Timolol Fixed Combination (Fc) Vs. Extemporaneous Combination (Ec) Or Monotherapy (Mt) In The Treatment Of Primary Open-angle Glaucoma (POAG) And Ocular Hypert…
[cited by applicant]
Luciano Quaranta et al., “Prostaglandin Analogs and Timolol-Fixed Versus Unfixed Combinations or Monotherapy for Open-Angle Glaucoma: A Systematic Review and Meta-Analysis,” Journal of Ocular Pharmacology and Therapeuti…
[cited by applicant]
Louise J. Lu et al. “Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma” Yale Journal of Biology and Medicine, vol. 90, 2017, (pp. 111-118).
[cited by applicant]
Hoy, Sheirdan M., “Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension”, Drugs, 2015, vol. 75, pp. 1807-1813. (7 pages total).
[cited by applicant]
Konstas, et al., “Latanoprost/timolol fixed combination for the treatment of glaucoma”, 2013, Expert Opinion on Pharmacotherapy, 14 pages total.
[cited by applicant]
Hollo et al., “Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma”, 2015, Expert Opinion on Drug Safety, 10 pages total.
[cited by applicant]
Martinez, et al., “Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension”, 2007, 9 pages total.
[cited by applicant]
Denis, et al., “Travoprost/timolol fixed combination in the management of open-angle glaucoma: a clinical review”, Expert Opinion on Pharmacotherapy, 10 pages total.
[cited by applicant]
Berlin et al., “EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study”, 2016, Br. J. Ophthalmol., 5 pa…
[cited by applicant]
Harris, et al., “Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo controlled, Dose Escalation Study”, 2016, J. Glaucoma, 8 pages total.
[cited by applicant]
Suto,, et al., “A Novel Dual Agonist of EP5 and FP Receptors for OAG and OHTs Safety? Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers”, 2015, Investigative Opthamology & Visual Science, 8 pages …
[cited by applicant]
Rathore, et al., “Timolol maleate a gold standard drug in glaucoma used as ocular films and inserts: an overview”, 2010, International Journal of Pharmaceutical Sciences Review and Research, 8 pages total.
[cited by applicant]